Drug Profile

NT CoV2 1

Alternative Names: NT-CoV2-1

Latest Information Update: 15 Apr 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator National Institute of Allergy and Infectious Diseases
Developer Oragenics Inc
Class Adjuvants; COVID-19 vaccines; Protein vaccines; Subunit vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Suspended COVID 2019 infections

Most Recent Events

31 Dec 2023 Suspended - Preclinical for COVID-2019 infections (Prevention) in USA (Intranasal)
31 Mar 2023 ORAGENICS completes a Type-B pre-IND Meeting with the US FDA for COVID-2019 infection, prior to March 2023
22 Dec 2022 Adverse events data from a preclinical trial in COVID-2019 infections released by Oragenics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com